HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features

被引：0
|
作者：
Zare, Somaye [1 ]
Lin, Leo [1 ]
Alghamdi, Abrar G. [2 ]
Roma, Andres [2 ]
Dell'Aquila, Marie [1 ]
Hasteh, Farnaz [2 ]
Fadare, Oluwole [1 ]
机构：
[1] UC San Diego Hlth, San Diego, CA USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
328
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [31] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
    Donaldson, Alana R.
    Shetty, Shashirekha
    Rivera, Christine
    Portier, Bryce P.
    Cook, James R.
    Budd, G. T.
    Downs-Kelly, Erinn
    Klein, Roger D.
    Lanigan, Christopher P.
    Tubbs, Raymond
    Calhoun, Benjamin C.
    LABORATORY INVESTIGATION, 2016, 96 : 40A - 41A
  • [32] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
    Donaldson, Alana R.
    Shetty, Shashirekha
    Rivera, Christine
    Portier, Boyce P.
    Cook, James R.
    Budd, G. T.
    Downs-Kelly, Erinn
    Klein, Roger D.
    Lanigan, Christopher P.
    Tubbs, Raymond
    Calhoun, Benjamin C.
    MODERN PATHOLOGY, 2016, 29 : 40A - 41A
  • [33] Breast Carcinomas with Equivocal HER2/Neu Amplication: Morphologic Features, CEP17 Polysomy and HER2 Genetic Heterogeneity
    Astvatsaturyan, K.
    Bose, S.
    MODERN PATHOLOGY, 2012, 25 : 24A - 25A
  • [34] Breast Carcinomas with Equivocal HER2/Neu Amplification: Morphologic Features, CEP17 Polysomy and HER2 Genetic Heterogeneity
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2012, 92 : 24A - 25A
  • [35] HER2 Testing by FISH: Discordance between HER2 Signals Per Cell and HER2:CEP 17 Ratio
    Dintzis, S. M.
    Allison, K. H.
    Schmidt, R. A.
    CANCER RESEARCH, 2010, 70
  • [36] Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH using a Standard HER2/CEP17 Dual Probe and an Alternative HER2/LIS1 Dual Probe: An Analysis of 1201 Cancers
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    LABORATORY INVESTIGATION, 2018, 98 : 117 - 117
  • [37] HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe, Marian Priyanthi
    de Boer, Willem Bastiaan
    Khor, Tze Sheng
    Ooi, Esther M.
    Jene, Nic
    Jayasinghe, Sureshini
    Fox, Stephen B.
    PATHOLOGY, 2014, 46 (03) : 184 - 187
  • [38] HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio
    Layfield, L. J.
    Schmidt, R.
    LABORATORY INVESTIGATION, 2012, 92 : 49A - 49A
  • [39] Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Daehne, Svenja
    Roma, Andres A.
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (09) : 1208 - 1215
  • [40] HER2/neu Gene Amplification Heterogeneity: The Significance of Cells With a 3:1 HER2/CEP17 Ratio
    Layfield, Lester J.
    Schmidt, Robert L.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (06) : 543 - 549
12345